What does options canceled (in dollars per share) mean?

This metric represents the weighted-average exercise price or fair value per share of stock options that were forfeited or canceled during the reporting period. It provides insight into the turnover of equity-based incentives and the potential impact on dilution management. Monitoring this helps investors understand the stability of the company's long-term incentive programs.

Bicara Therapeutics BCAX Options canceled (in dollars per share)

Options canceled (in dollars per share) at other companies

Ondas, Inc. ONDS

$5.42+274%

XylemXYL

$127.87+13.3%

Oruka Therapeutics, Inc.ORKA

$15.04—

Bicara TherapeuticsBCAX

$0.00—

NextNavNN

$6.87—

ALH

Alliance Laundry Holdings Inc.ALH

$0.00—

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.68B+81.4%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's options canceled (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's options canceled (in dollars per share)?: Bicara Therapeutics (BCAX) reported options canceled (in dollars per share) of $0.00 in Q1 2026.
What does options canceled (in dollars per share) mean?: This metric represents the weighted-average exercise price or fair value per share of stock options that were forfeited or canceled during the reporting period. It provides insight into the turnover of equity-based incentives and the potential impact on dilution management. Monitoring this helps investors understand the stability of the company's long-term incentive programs.